Author

admin

Browsing

Investor Insight InMed is a pharmaceutical drug development company advancing proprietary small-molecule drugs in Alzheimer’s and ophthalmology, backed by a revenue-generating manufacturing subsidiary. The company is an undervalued opportunity with cash exceeding market capitalization and multiple upcoming catalysts. Overview InMed Pharmaceuticals (NASDAQ:INM) is a biopharmaceutical company with a differentiated business…